f Post-Approval Studies (PAS) Database
Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Post-Approval Studies (PAS) Database
  • Print
  • Share
  • E-mail
-

The FDA has the authority to require sponsors to perform a post-approval study (or studies) at the time of approval of a premarket approval (PMA), humanitarian device exemption (HDE), or product development protocol (PDP) application. Post-approval studies can provide patients, health care professionals, the device industry, the FDA and other stakeholders information on the continued safety and effectiveness (or continued probable benefit, in the case of an HDE) of approved medical devices. This database allows you to search Post-Approval Study information by applicant or device information.

Learn more...


           

5 year long term (IDE)


Suggest Enhancement / Report Issue | export reports to excelExport to Excel
General
Study Status Terminated
Application Number /
Requirement Number		 P040040 / PAS001
Date Original Protocol Accepted 09/07/2007
Date Current Protocol Accepted 09/07/2007
Study Name 5 year long term (IDE)
Device Name AMPLATZER MUSCULAR VSD OCCLUDER
General Study Protocol Parameters
Study Design Prospective Cohort Study
Data Source Sponsor Registry
Comparison Group Concurrent Control
Analysis Type Descriptive
Study Population Child: 2-12 yrs, Adolescent: 13-18 yrs, Transit. Adolescent B (as adults) : 18-21 yrs, Adult: >21
Detailed Study Protocol Parameters
Study Objectives This study will provide long-term follow-up of forty-three subjects from the premarket cohort that have been designated as High Risk.
Study Population This device is indicated for use in patients with a complex VSD of significant size to warrant closure (large volume left to right shunt, pulmonary hypertension and/or clinical symptoms of congestive heart failure) who are considered to be at high risk for standard transatrial or transarterial surgical closure based on anatomical conditions and/or based on overall medical condition.
Sample Size 43 patients, 21 sites
Key Study Endpoints Safety endpoints include adverse events.
Follow-up Visits and Length of Follow-up Annual office visits were required out to 5 years.
Interim or Final Data Summary
Interim Results The study was terminated early due a low follow-up rate
Actual Number of Patients Enrolled 43
Actual Number of Sites Enrolled 38
Patient Follow-up Rate 24%
Final Safety Findings A total of 35 overall events were reported in 20 of 43 subjects (46.5%). The most frequently reported event was hypotension which was reported in 11.6% of subjects (5 reports in 5 of 43 subjects).
Study Strengths & Weaknesses Strengths: Lessons learned on requesting for long term follow-up consent at tiem of IDE enrollment
Weaknesses: Extremely low follow-up of the cohort.
Recommendations for Labeling Changes No labeling changes were recommended.


5 year long term (IDE) Reporting Schedule

Reporting Schedule
Report
Date Due
FDA Receipt
Date
Applicant's Reporting Status
6 month report 03/07/2008 03/05/2008 On Time
1 year report 09/07/2008 09/08/2008 Overdue/Received
18 Month Report 03/05/2009 03/05/2009 On Time
2 year report 09/07/2009 10/15/2009 Overdue


Contact Us
Mandated Studies Program
Food and Drug Administration
10903 New Hampshire Ave.
Silver Spring, MD 20993-0002
Email: MandatedStudiesPrograms@fda.hhs.gov

Additional Resources

-
-